Mind Medicine (MNMD) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mind Medicine has commenced its Phase 3 Voyage study, dosing the first patient with MM120, an optimized form of LSD, for treating Generalized Anxiety Disorder (GAD). This study aims to assess the drug’s efficacy and safety compared to a placebo, building on promising Phase 2b results. The company plans to enroll approximately 200 participants in the U.S., with a second trial set to start in 2025 in the U.S. and Europe.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.